羌活地黄汤对佐剂性类风湿关节炎大鼠作用机制研究

摘要 目的：研究羌活地黄汤对佐剂性类风湿关节炎（RA）大鼠辅助性T细胞/调节性T细胞（Th17/Treg）失衡、血清基质金属蛋白酶-3（MMP-3）、基质金属蛋白酶-13（MMP-13）以及滑膜组织血管内皮生长因子（VEGF）、核因子-κB受体活化因子配基（RANKL） mRNA表达的影响。方法：取40只SD级大鼠进行研究，将其以随机数字表法分为正常对照组、模型组、羌活地黄汤组以及甲氨蝶呤组，每组各10只。除正常对照组外，其余各组大鼠均建立佐剂性RA动物模型。羌活地黄汤组予以羌活地黄汤灌胃干预，甲氨蝶呤组予以甲氨蝶呤灌胃干预，正常对照组及模型组均予以等量生理盐水灌胃干预。各组均进行为期28d的干预，比较各组体重、关节炎指数及关节肿胀度、外周血Th17/Treg相关指标、血清MMP-3、MMP-13水平、滑膜组织VEGF、RANKL mRNA表达。结果：模型组体重低于正常对照组，羌活地黄汤组、甲氨蝶呤组关节炎指数及关节肿胀度均低于模型组，而体重高于模型组（均P＜0.05）。模型组、羌活地黄汤组、甲氨蝶呤组的外周血CD4+IL-17+T、Th17/Treg均高于正常对照组，而Foxp3+CD4+CD25+Treg低于正常对照组，且羌活地黄汤组、甲氨蝶呤组的外周血CD4+IL-17+T、Th17/Treg均低于模型组，而Foxp3+CD4+CD25+Treg高于模型组（均P＜0.05）。模型组、羌活地黄汤组、甲氨蝶呤组的血清MMP-3、MMP-13水平均高于正常对照组，而羌活地黄汤组、甲氨蝶呤组的血清MMP-3、MMP-13水平均低于模型组（均P＜0.05）。模型组、羌活地黄汤组、甲氨蝶呤组的滑膜组织VEGF、RANKL mRNA表达水平均高于正常对照组，而羌活地黄汤组、甲氨蝶呤组的滑膜组织VEGF、RANKL mRNA表达水平均低于模型组（均P＜0.05）。结论：羌活地黄汤可改善佐剂性RA大鼠的症状以及Th17/Treg失衡状态，且有效改善其血清MMP-3、MMP-13水平以及滑膜组织VEGF、RANKL mRNA表达。     

The effect of Banxia-houpo decoction on CUMS-induced depression by promoting M2 microglia polarization via TrkA/Akt signalling

It has been reported that Banxia-houpo decoction (BXHPD) serves as the anti-depressant treatment for a mild and severe depressive disease with limited side effects. The present study was performed to evaluate the protective effect of BXHPD on chronic unpredicted mild stress (CUMS)-induced depression and explore its effect on TrkA/Akt-mediated microglia polarization. The CUMS procedure was carried out, and the mice were intragastrically treated with BXHPD once daily. The selective TrkA inhibitor GW441756 was applied to further investigate the role of TrkA in BXHPD-mediated microglia polarization. The behaviour test including open field test (OFT), sucrose preference test (SPT), novelty-suppressed feeding test (NSFT), tail suspension test (TST) and forced swim test (FST) was performed. The concentrations of pro-inflammatory cytokines IL-6, TNF-α, IL-1β, IL-12 and anti-inflammatory cytokines IL-4, IL-10 were determined using Enzyme-linked immunosorbent assay. The population of Iba1+ cells and the length of microglia processes were observed under the fluorescence microscope. The mRNA expressions of Arg1, Ym1 and Fizzl1 were measured by PCR. The protein expressions of TrkA, p-Tyr490-TrkA, p-Ser473-Akt, p-Ser473-Akt1, p-Ser474-Akt2, p-CREB and Jmjd3 were detected by western blot. Our results showed that BXHPD attenuated CUMS-induced depressive-like behaviour, promoted anti-inflammatory cytokines, inhibited pro-inflammatory cytokines, suppressed microglia activation, promoted M2 phenotype-specific indices and upregulated the expressions of TrkA, p-Tyr490-TrkA, p-Ser473-Akt, p-Ser473-Akt1, p-Ser474-Akt2, p-CREB and Jmjd3. The above beneficial effect of BXHPD can be blocked by TrkA inhibitor GW441756. This work demonstrated that BXHPD exerted an anti-depressant effect by promoting M2 phenotype microglia polarization via TrkA/Akt pathway.     

基于网络药理学的四君子汤治疗阿尔茨海默病作用机制研究

基于网络药理学探讨四君子汤治疗阿尔茨海默病(AD)的作用机制。借助TCMSP数据库及Uniprot数据库筛选出四君子汤有效成分及靶点基因。通过Drugbank、Dis Ge NET和TTD数据库筛选出阿尔茨海默病的靶点基因;成分靶点与疾病靶点映射后使用Cytoscape 3.7.1软件构建药物有效成分-靶点蛋白相互作用网络,使用String数据库绘制靶点蛋白-靶点蛋白相互作用网络;对靶点蛋白利用Metascape数据库进行GO分析和KEGG分析,最后采用荧光实时定量PCR对网络药理学主要分析结果进行验证。分析结果表明,四君子汤主要关联AD的β淀粉样蛋白聚集、细胞凋亡、炎症反应、氧化应激反应、自噬、胰岛素代谢等;体外实验提示,四君子汤参与调控APP介导的β淀粉样蛋白聚集,Caspase-3、Bcl-2、Bax介导的细胞凋亡,MAOB介导的氧化应激反应,mTOR介导的自噬,以及INSR介导的胰岛素代谢等通路。综上四君子汤治疗AD具有多成分、多靶点的特点,可为进一步研究其作用机制提供依据。     

玉泉汤加减对OSF癌变的干预效果及对c-Myc、Cyclin D1、β-catenin表达的影响

目的:研究玉泉汤加减对口腔黏膜下纤维化(oral submucous fibrosis,OSF)癌变的干预效果及对原癌基因(c-Myc)、细胞周期蛋白D1(Cyclin D1)、β-连环蛋白(β-catenin)表达的影响。方法:本研究选取2018年4月至2019年4月在我院就诊的OSF癌变患者92例,按照完全随机法将患者分为西药组和中药组,每组各46例。西药组给予曲安奈德注射液联合盐酸利多卡因注射,中药组在西药组的基础上加服中药玉泉汤加减,检测和比较两组患者治疗前后β-catenin、纤维蛋白原(FIB)、c-Myc、白介素-6(IL-6)、转化生长因子-β1(TGF-β1)、Cyclin D1表达的变化,治疗效果以及不良反应的发生情况。结果:中药组治疗后的总有效率(91.30%)显著高于西药组(67.39%,P0.05)。两组患者治疗后β-catenin、FIB、c-Myc、IL-6、TGF-β1及Cyclin D1的表达均低于治疗前(P0.05);中药组治疗后β-catenin、FIB、c-Myc、IL-6、TGF-β1及Cyclin D1的表达均明显低于西药组(P0.05)。中药组治疗后开口度比西药组小、灼痛感轻及纤维条索少(P0.05)。中药组治疗后的不良反应率(2.17%)显著低于西药组(13.04%,P0.05)。结论:玉泉汤加减治疗OSF癌变的效果及安全性均显著优于曲安奈德注射液联合盐酸利多卡因注射治疗,可能与其能显著下调c-Myc、Cyclin D1、β-catenin的表达,改善患者的临床症状有关。